UroToday10h
APCCC Diagnostics 2025: What Imaging Should You Use in Case of Suspected Metastases?
For patients with metachronous low burden mCSPC on conventional imaging being recommended for systemic therapy, 51% responded ...
UroToday1d
APCCC Diagnostics 2025: When to Assess Biology with a Re-Biopsy?
(UroToday.com) The 2025 APCCC Diagnostics annual meeting featured a session on how to monitor metastatic prostate cancer and ...
UroToday1d
APCCC Diagnostics 2025: PSA Relapse: When Do You Need to Act?
(UroToday.com) The Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics 2025, held in Lugano, Switzerland, on February 27 th and 28 th, was host to a session addressing the contemporary ...
UroToday1d
APCCC Diagnostics 2025: Genomic Classifiers at the Time of Biochemical Recurrence
(UroToday.com) The Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics 2025 held in Lugano, Switzerland was host to a session addressing the contemporary management of biochemically ...
UroToday2d
Leveraging Genomic Insights to Guide Treatment Intensification in Post-Prostatectomy Patients
Phuoc Tran joins Angela Jia to discuss findings from the RTOG 0534 SPPORT trial examining Decipher® genomic classifier scores as predictors of treatment response in post-prostatectomy salvage ...
UroToday5d
Change of the guards-Looking back at Michael Droller: Visionary and supporter-The perspective of the International Bladder Cancer Network.
Professor Michael Droller is stepping down as Editor-in-chief of Urologic Oncology: Seminars and Original Investigations, a journal that he co-founded. This manuscript describes his relation with the ...
UroToday6d
Sarcopenia May Increase Cisplatin Toxicity in Bladder Cancer Patients with Borderline Renal Function - Beyond the Abstract
Neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy (RC) remains a standard of care treatment for patients with muscle-invasive bladder cancer (MIBC). Cisplatin also figures ...
UroToday6d
A neoantigen vaccine generates antitumour immunity in renal cell carcinoma.
Personalized cancer vaccines (PCVs) can generate circulating immune responses against predicted neoantigens1-6. However, whether such responses can target cancer driver mutations, lead to immune ...
UroToday6d
Dynamics of Resistance to Immunotherapy and TKI in Patients with Advanced Renal Cell Carcinoma - Beyond the Abstract
Immune-based combinations are the cornerstone of the first-line treatment of metastatic renal cell carcinoma patients, and they lead to outstanding outcomes. Nevertheless, primary resistance and ...
UroToday5d
Impact of upper tract urothelial carcinoma history on patients with non-muscle invasive bladder cancer undergoing intravesical chemotherapy.
This study was designed to evaluate the impact of upper tract urothelial carcinoma (UTUC) history on prognosis in patients with non-muscle-invasive bladder cancer (NMIBC) receiving intravesical ...
UroToday5d
Blood Based Tumor Mutational Burden as a Predictive Marker for Immune Checkpoint Inhibitors in Prostate Cancer - Beyond the Abstract
Immune checkpoint inhibitors (ICIs) have dramatically altered the treatment landscape for several tumor types but remain largely ineffective for the majority of patients with prostate and breast ...
UroToday6d
VI-RADS-Based Algorithm for Bladder Cancer Management Randomized Retrospective Study - Beyond the Abstract
To evaluate if VI-RADS can distinguish between non-muscle-invasive bladder cancers (NMIBC), muscle-invasive bladder cancer (MIBC), and high-risk non-muscle-invasive bladder cancers (HR-NMIBCs). It is ...